Welcome to our dedicated page for First Tracks Biotherapeutics SEC filings (Ticker: TRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on First Tracks Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into First Tracks Biotherapeutics's regulatory disclosures and financial reporting.
First Tracks Biotherapeutics, Inc. (TRAX) director Ware J. Anthony exercised stock options to acquire 39,265 shares of common stock at an exercise price of $5.74 per share on September 2, 2026, then sold the same 39,265 shares at a weighted average price of $44.7764 per share, with individual sale prices ranging from $44.62 to $45.28. The stock options exercised were fully vested, and no Rule 10b5-1 trading plan is reported for these transactions. In addition, he continues to hold options to purchase up to 99,320 shares of common stock and 6,500 restricted stock units.
First Tracks Biotherapeutics, Inc. (TRAX) received a notice under Rule 144 that director Joe Anthony Ware plans to sell common stock. The planned sale covers 39,265 shares of common stock, expected to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services on or after September 2, 2026.
The shares are to be issued from a stock option exercise with the issuer as the counterparty and settled in cash. The filing lists an approximate aggregate market value of $1,758,145.35 for the shares and notes that 35,730,843 shares of the issuer’s common stock are outstanding, as context for the planned disposition.
First Tracks Biotherapeutics, Inc. (symbol: TRAX) is the issuer of record for a Form 4 filing submitted to the SEC.
First Tracks Biotherapeutics, Inc. (symbol: TRAX) is the issuer of record for a Form 4 filing submitted to the SEC.
First Tracks Biotherapeutics, Inc. (symbol: TRAX) is the issuer of record for a Form 4 filing submitted to the SEC.
First Tracks Biotherapeutics, Inc. has a significant shareholder group led by TCG Crossover funds and Chen Yu reporting beneficial ownership of its common stock. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., together with their general partners, each report beneficial ownership of 1,447,652 shares, or 4.1% of the common stock, with shared voting and dispositive power and no sole power. Chen Yu, as sole managing member of both general partners, may be deemed to beneficially own an aggregate 2,895,304 shares, representing 8.3% of the company’s common stock, all with shared voting and dispositive power. These percentages are based on 34,892,381 shares outstanding as of May 12, 2026, and each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Sirenia Capital Management LP and Alex Silverstein report a significant ownership position in First Tracks Biotherapeutics, Inc. common stock. They report beneficial ownership of 2,495,777 shares of common stock, representing 7.2% of the class, based on 34,892,381 shares outstanding as of May 12, 2026 as reported by the company.
All reported shares are held with shared voting and dispositive power; neither Sirenia nor Mr. Silverstein reports sole voting or dispositive power. The position is held through investment funds and a managed account overseen by Sirenia, with Point72 Associates II, LLC’s account having the right to receive dividends or sale proceeds for more than 5% of the outstanding common stock.
Affinity Asset Advisors, LLC and its managing member Michael Cho report a passive ownership stake in First Tracks Biotherapeutics, Inc. common stock. As of June 30, 2026, they beneficially own 2,032,012 shares of common stock, representing approximately 5.8% of the company’s outstanding shares.
The shares are held directly by Affinity Healthcare Fund, LP, for which Affinity Asset Advisors, LLC acts as investment manager with sole voting and dispositive power over the position. Michael Cho may be deemed a beneficial owner through his role as managing member of the adviser. The ownership percentage is based on 34,892,381 shares of common stock outstanding as of May 12, 2026, as disclosed in the issuer’s Form 10-Q.
First Tracks Biotherapeutics, Inc., a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, has registered for resale by selling stockholders up to 10,497,054 shares of common stock; the company will not receive any proceeds from these sales. The business was separated from AnaptysBio via a Spin-Off completed on April 20, 2026, and concurrently raised approximately $80 million gross in a private placement of 5,791,479 primary shares at $13.81 per share.
As of June 30, 2026, cash and cash equivalents were $168.0 million and total assets were $183.1 million, with 35,390,679 shares of common stock outstanding. For the six months ended June 30, 2026, the company reported a net loss of $83.9 million, driven by research and development expenses of $59.6 million and general and administrative expenses of $28.1 million, partially offset by $3.9 million of interest income. Management states existing resources are expected to fund operating plans for at least 12 months. The pipeline includes ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis, and ANB101, a BDCA2 modulator.
First Tracks Biotherapeutics, Inc., a clinical-stage biotechnology company recently spun off from AnaptysBio, focuses on antibody therapies for autoimmune and inflammatory diseases, including ANB033 (celiac disease and eosinophilic esophagitis), rosnilimab (rheumatoid arthritis) and ANB101 (BDCA2 modulator).
For the three and six months ended June 30, 2026, the company reported net losses of $33.4 million and $83.9 million, respectively, driven by research and development expenses of $25.6 million and $59.6 million and general and administrative expenses of $9.3 million and $28.1 million.
Cash and cash equivalents were $168.0 million at June 30, 2026, down from $238.2 million at December 31, 2025, after $64.5 million of operating cash outflows in the first half. The April 2026 spin-off and an associated private placement generated approximately $80 million in gross proceeds, and management states current resources are expected to fund operations for at least 12 months.